Oculis (NASDAQ:OCS) Shares Gap Up – Here’s Why

Oculis Holding AG (NASDAQ:OCS) shares gapped up before the market opened on Friday . The stock had previously closed at $18.70, but opened at $20.35. Oculis shares last traded at $20.41, with a volume of 64,061 shares traded.

Analysts Set New Price Targets

A number of research analysts recently commented on OCS shares. Chardan Capital reaffirmed a “buy” rating and issued a $28.00 price target on shares of Oculis in a research note on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Oculis in a report on Monday. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $28.80.

Oculis Stock Up 10.8 %

The firm has a 50-day simple moving average of $16.38 and a 200 day simple moving average of $13.87. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.02 and a quick ratio of 4.02. The stock has a market capitalization of $839.24 million, a P/E ratio of -10.74 and a beta of -0.33.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.